47 related articles for article (PubMed ID: 17657743)
1. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
[TBL] [Abstract][Full Text] [Related]
2. Lectin-nanoparticle concept for free PSA glycovariant providing superior cancer specificity.
Kekki H; Montoya Perez I; Taimen P; Boström PJ; Gidwani K; Pettersson K
Clin Chim Acta; 2024 Apr; 559():119689. PubMed ID: 38677453
[TBL] [Abstract][Full Text] [Related]
3. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.
Shariat SF; Canto EI; Kattan MW; Slawin KM
Rev Urol; 2004; 6(2):58-72. PubMed ID: 16985579
[TBL] [Abstract][Full Text] [Related]
4. Retracted: Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9839167. PubMed ID: 38094390
[TBL] [Abstract][Full Text] [Related]
5. Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction.
Ferraro S; Bussetti M; Bassani N; Rossi RS; Incarbone GP; Bianchi F; Maggioni M; Runza L; Ceriotti F; Panteghini M
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298597
[TBL] [Abstract][Full Text] [Related]
6. Prediction models for prostate cancer to be used in the primary care setting: a systematic review.
Aladwani M; Lophatananon A; Ollier W; Muir K
BMJ Open; 2020 Jul; 10(7):e034661. PubMed ID: 32690501
[TBL] [Abstract][Full Text] [Related]
7. Evaluating Ultra-long-Chain Fatty Acids as Biomarkers of Colorectal Cancer Risk.
Perttula K; Edmands WM; Grigoryan H; Cai X; Iavarone AT; Gunter MJ; Naccarati A; Polidoro S; Hubbard A; Vineis P; Rappaport SM
Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1216-23. PubMed ID: 27257090
[TBL] [Abstract][Full Text] [Related]
8. A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.
Lee SW; Hosokawa K; Kim S; Jeong OC; Lilja H; Laurell T; Maeda M
Sensors (Basel); 2015 May; 15(5):11972-87. PubMed ID: 26007739
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.
Thorek DL; Evans MJ; Carlsson SV; Ulmert D; Lilja H
Thromb Haemost; 2013 Sep; 110(3):484-92. PubMed ID: 23903407
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification in prostate cancer screening.
Roobol MJ; Carlsson SV
Nat Rev Urol; 2013 Jan; 10(1):38-48. PubMed ID: 23247693
[TBL] [Abstract][Full Text] [Related]
11. An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.
Inman BA; Zhang J; Shah ND; Denton BT
BJU Int; 2012 Aug; 110(3):375-81. PubMed ID: 22313933
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers in prostate cancer I: blood-based markers.
Shariat SF; Semjonow A; Lilja H; Savage C; Vickers AJ; Bjartell A
Acta Oncol; 2011 Jun; 50 Suppl 1(Suppl 1):61-75. PubMed ID: 21604943
[TBL] [Abstract][Full Text] [Related]
13. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
Lilja H; Cronin AM; Dahlin A; Manjer J; Nilsson PM; Eastham JA; Bjartell AS; Scardino PT; Ulmert D; Vickers AJ
Cancer; 2011 Mar; 117(6):1210-9. PubMed ID: 20960520
[TBL] [Abstract][Full Text] [Related]
14. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
Savage CJ; Lilja H; Cronin AM; Ulmert D; Vickers AJ
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1201-7. PubMed ID: 20406957
[TBL] [Abstract][Full Text] [Related]
15. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
[TBL] [Abstract][Full Text] [Related]
16. Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Ulmert D; O'Brien MF; Bjartell AS; Lilja H
Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
[TBL] [Abstract][Full Text] [Related]
17. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
Botchorishvili G; Matikainen MP; Lilja H
Curr Opin Urol; 2009 May; 19(3):221-6. PubMed ID: 19318948
[TBL] [Abstract][Full Text] [Related]
18. Screening for prostate cancer: an update.
Shariat SF; Scardino PT; Lilja H
Can J Urol; 2008 Dec; 15(6):4363-74. PubMed ID: 19046489
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
Vickers AJ; Ulmert D; Serio AM; Björk T; Scardino PT; Eastham JA; Berglund G; Lilja H
Int J Cancer; 2007 Nov; 121(10):2212-7. PubMed ID: 17657743
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
